Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942954 | 0.88 | PLA2G2C (0.37) | CA2HCRTR2CTSKCTSSCACNA1B | |
| SCHEMBL212186 | 0.83 | PPARA (0.49) | CTSSSYKKLK7KLK5 | |
| SCHEMBL2727081 | 0.83 | PPARA (0.49) | CTSSSYKKLK7KLK5 | |
| SCHEMBL14718553 | 0.78 | HCRTR2 (0.39) | CA2HCRTR2F10 | |
| SCHEMBL9606659 | 0.76 | CA2 (0.37) | CA2 | |
| SCHEMBL13903965 | 0.75 | CA2 (0.48) | CA2HCRTR2CTSKCA1 | |
| SCHEMBL21251585 | 0.74 | HCRTR2 (0.42) | CA2HCRTR2CA1 | |
| SCHEMBL29342920 | 0.74 | CTSS (0.34) | CA2HCRTR2CTSKCTSSCA1 | |
| SCHEMBL15195657 | 0.73 | TDP1 (0.46) | CA2HCRTR2CA1 | |
| SCHEMBL3009671 | 0.73 | TDP1 (0.46) | CA2HCRTR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CA2 81/4885HCRTR2 3149/4885CTSK 1455/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CA2 81/4885HCRTR2 3149/4885CTSK 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.